Tollys welcomes Dr. Jean-Pierre Armand as member of its scientific advisory board
Isorg obtains FBI certification for security market’s first organic photodiode-based module for fingerprint scanners
Lynred investit 2,8 millions d’euros dans le développement d’une nouvelle génération de détecteurs infrarouges dans le cadre de l’appel à projets Plan de relance pour l’industrie
CVasThera secures €1.3 Million in first funding round
Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01
Noventure signs exclusive license agreement for innovative food supplement EPA3G
• EPA3G a unique, patented emulsion of high purity EPA, in drinkable single sachet – containing daily dose of 3g
• Deal gives Noventure licensing rights in over 50 countries
• Agreement signed with global partner Azur Global Nutrition
Biomunex Pharmaceuticals signs strategic license and co-development agreement with Onward Therapeutics for proprietary bispecific antibody program
Accure Therapeutics publishes pivotal preclinical efficacy study in epilepsy
• No currently marketed drugs are able to stop the progression of epilepsy, those available only help manage seizures
• More than 30% of patients do not respond adequately to those drugs carrying risks of structural damage to the brain and nervous system, comorbidities and increased mortality
• Accure Tx’s candidate ACT-03 demonstrates in animal models anti-epileptogenic activity while protecting against cognitive decline
